These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 29802399

  • 21. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.
    Wang X, Zheng Z, Caviglia JM, Corey KE, Herfel TM, Cai B, Masia R, Chung RT, Lefkowitch JH, Schwabe RF, Tabas I.
    Cell Metab; 2016 Dec 13; 24(6):848-862. PubMed ID: 28068223
    [Abstract] [Full Text] [Related]

  • 22. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
    Kawakubo M, Tanaka M, Ochi K, Watanabe A, Saka-Tanaka M, Kanamori Y, Yoshioka N, Yamashita S, Goto M, Itoh M, Shirakawa I, Kanai S, Suzuki H, Sawada M, Ito A, Ishigami M, Fujishiro M, Arima H, Ogawa Y, Suganami T.
    Sci Rep; 2020 Jan 22; 10(1):983. PubMed ID: 31969650
    [Abstract] [Full Text] [Related]

  • 23. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA, Singh BK, Adami E, Viswanathan S, Dong J, D'Agostino GA, Ng B, Lim WW, Tan J, Paleja BS, Tripathi M, Lim SY, Shekeran SG, Chothani SP, Rabes A, Sombetzki M, Bruinstroop E, Min LP, Sinha RA, Albani S, Yen PM, Schafer S, Cook SA.
    Gastroenterology; 2019 Sep 22; 157(3):777-792.e14. PubMed ID: 31078624
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
    Alkhouri N, LaCerte C, Edwards J, Poordad F, Lawitz E, Lee L, Karan S, Sawhney S, Erickson M, MacConell L, Zaru L, Chen J, Campagna J.
    Liver Int; 2024 Apr 22; 44(4):966-978. PubMed ID: 38293761
    [Abstract] [Full Text] [Related]

  • 26. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.
    Itoh M, Suganami T, Nakagawa N, Tanaka M, Yamamoto Y, Kamei Y, Terai S, Sakaida I, Ogawa Y.
    Am J Pathol; 2011 Nov 22; 179(5):2454-63. PubMed ID: 21906580
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans.
    Itoh M, Kato H, Suganami T, Konuma K, Marumoto Y, Terai S, Sakugawa H, Kanai S, Hamaguchi M, Fukaishi T, Aoe S, Akiyoshi K, Komohara Y, Takeya M, Sakaida I, Ogawa Y.
    PLoS One; 2013 Nov 22; 8(12):e82163. PubMed ID: 24349208
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz EJ, Hellstern PA, Owens-Grillo J, Van Biene C, Shringarpure R, MacConell L, Shapiro D, Cohen DE.
    Liver Int; 2019 Nov 16; 39(11):2082-2093. PubMed ID: 31402538
    [Abstract] [Full Text] [Related]

  • 35. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A, Magee N, Deng F, Lehn S, Zhong C, Zhang Y.
    J Biol Chem; 2018 Jun 01; 293(22):8656-8671. PubMed ID: 29666185
    [Abstract] [Full Text] [Related]

  • 36. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
    Motiño O, Agra N, Brea Contreras R, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde ÁM, Francés DE, Martín-Sanz P.
    Biochim Biophys Acta; 2016 Sep 01; 1862(9):1710-23. PubMed ID: 27321932
    [Abstract] [Full Text] [Related]

  • 37. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
    Liu SY, Huang CC, Yang YY, Huang SF, Lee TY, Li TH, Hou MC, Lin HC.
    PLoS One; 2022 Sep 01; 17(12):e0276717. PubMed ID: 36490253
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis.
    Huang P, Kaluba B, Jiang XL, Chang S, Tang XF, Mao LF, Zhang ZP, Huang FZ.
    Biomed Res Int; 2018 Sep 01; 2018():8071093. PubMed ID: 29670908
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.